FibroScan overestimated advanced fibrosis and cirrhosis in patients with class 3 obesity and metabolic dysfunction-associated steatotic liver disease.

New research reveals distinct epidemiological trends in liver cancer across Mexico, with gender and regional variations ...

A significant subset of MASLD patients progresses to metabolic dysfunction-associated steatohepatitis (MASH), liver fibrosis, and even hepatocellular carcinoma (HCC), yet no universally approved ...

(Journal of Hepatology) Meanwhile, modeling data predicted that by 2050 the prevalence of MASLD in the U.S. population ... for hepatocellular carcinoma (HCC) surveillance in patients with cirrhosis.

A study published in Nature Aging has revealed a promising new drug candidate that may help combat metabolic dysfunction-associated steatotic liver disease (MASLD), a chronic liver condition that ...

Through the PLANet and ELEGANCE programmes, Prof Chow and his team discovered that dysregulated bile acid is a key risk factor for HCC, particularly in MASLD HCC. This dysregulation is linked to ...

Globally, more than 30% of the adult population has metabolic dysfunction-associated steatotic liver disease (MASLD). People with MASLD and more so with metabolic dysfunction-associated ...

More than 30% of people worldwide have metabolic dysfunction–associated steatotic liver disease (MASLD; formerly nonalcoholic fatty liver disease), including 65% of those with type 2 diabetes ...

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD) ...